Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Cognitive Development Effects and Safety, and Pharmacokinetics of Adjunctive Rufinamide Treatment in Pediatric Subjects 1 to Less Than 4 Years of Age With Inadequately Controlled Lennox-Gastaut Syndrome

Trial Profile

A Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Cognitive Development Effects and Safety, and Pharmacokinetics of Adjunctive Rufinamide Treatment in Pediatric Subjects 1 to Less Than 4 Years of Age With Inadequately Controlled Lennox-Gastaut Syndrome

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rufinamide (Primary) ; Antiepileptic drugs
  • Indications Lennox-Gastaut syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms Study 303
  • Sponsors Eisai Inc
  • Most Recent Events

    • 27 Apr 2018 Results of a post hoc analysis, presented at the 70th Annual Meeting of the American Academy of Neurology
    • 27 Apr 2018 Results from NCT01151540, NCT01405053, NCT01146951 and 2 other studies, presented at the 70th Annual Meeting of the American Academy of Neurology
    • 05 Dec 2016 Primary endpoint has not been met. (Change in Child Behavior Checklist (CBCL) Total Problems Score), as reported in an Eisai Co Ltd media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top